Impedimed Ltd (ASX: IPD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Impedimed Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $188.15 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 2.02 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -35.17%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Impedimed Ltd (ASX: IPD)
    Latest News

    ⏸️ Investing

    2 growing biotech stocks for your portfolio in 2015

    Neuren Pharmaceuticals Ltd (ASX:NEU) and Impedimed Limited (ASX:IPD) could be just the ticket for improving your portfolio returns in the…

    Read more »

    ⏸️ Investing

    5 ASX stocks smashed by the market today

    ASX closes up 0.1%, but these five were smashed

    Read more »

    ⏸️ Investing

    Here's why this healthcare stock rocketed up 30% yesterday: Is there more to come?

    Impedimed Limited's (ASX:IPD) CEO Richard Carreon said: “This is a real game-changer".

    Read more »

    a woman
    ⏸️ Investing

    4 stocks soaring on the ASX today

    Want to know why some of these stocks are up more than 15%? Here's our view

    Read more »

    Frequently Asked Questions

    No, Impedimed does not pay shareholder dividends at this time.

    Impedimed Limited listed on the ASX on 24 October 2007.

    IPD ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Impedimed Ltd

    Impedimed Ltd (ASX: IPD) is a global leader in the design and manufacture of medical devices that use bioimpedance spectroscopy (BIS) technologies in the non-invasive clinical assessment of fluid and tissue composition.

    The company's products are typically used to assess and monitor lymphedema and heart failure, as well as to measure patients' tissue composition and fluid status. They also have general health applications in weight management, nutritional issues, and assessing bone content.

    As well, Impedimed offers a cloud-based digital platform to manage patient data. The company is based in Australia and generates most of its revenue in North America. 

    IPD Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    18 Apr 2024 $0.10 $0.00 0.00% 1,334,047 $0.10 $0.11 $0.10
    17 Apr 2024 $0.09 $0.00 0.00% 4,733,796 $0.09 $0.11 $0.09
    16 Apr 2024 $0.09 $0.01 11.24% 2,455,687 $0.09 $0.10 $0.09
    15 Apr 2024 $0.09 $0.00 0.00% 473,132 $0.09 $0.09 $0.09
    12 Apr 2024 $0.09 $0.00 0.00% 289,598 $0.09 $0.09 $0.09
    11 Apr 2024 $0.09 $-0.01 -10.20% 765,169 $0.10 $0.10 $0.09
    10 Apr 2024 $0.10 $0.01 11.11% 1,850,719 $0.09 $0.10 $0.09
    09 Apr 2024 $0.09 $0.00 0.00% 589,448 $0.09 $0.09 $0.09
    08 Apr 2024 $0.09 $0.00 0.00% 980,061 $0.09 $0.09 $0.09
    05 Apr 2024 $0.09 $0.00 0.00% 613,279 $0.09 $0.10 $0.09
    04 Apr 2024 $0.09 $0.01 11.49% 940,984 $0.09 $0.09 $0.09
    03 Apr 2024 $0.09 $0.00 0.00% 424,201 $0.09 $0.09 $0.09
    02 Apr 2024 $0.09 $-0.01 -10.87% 1,216,371 $0.09 $0.09 $0.09
    28 Mar 2024 $0.09 $0.01 11.63% 1,158,154 $0.09 $0.09 $0.09
    27 Mar 2024 $0.09 $0.00 0.00% 784,145 $0.09 $0.09 $0.09
    26 Mar 2024 $0.09 $0.00 0.00% 1,049,915 $0.09 $0.09 $0.09
    25 Mar 2024 $0.09 $0.00 0.00% 1,645,633 $0.09 $0.09 $0.08
    22 Mar 2024 $0.09 $-0.01 -10.75% 3,208,157 $0.09 $0.09 $0.09
    21 Mar 2024 $0.09 $0.00 0.00% 1,688,507 $0.09 $0.10 $0.09
    20 Mar 2024 $0.10 $0.00 0.00% 1,374,178 $0.10 $0.10 $0.09

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    25 Mar 2024 Janelle Delaney Buy 568,181 $49,999
    On-market trade.
    22 Mar 2024 Janelle Delaney Buy 581,395 $49,999
    On-market trade.
    04 Mar 2024 Janelle Delaney Buy 1,137,634 $99,591
    On-market trade.
    29 Feb 2024 Andrew Grant Buy 100,000 $87,000
    On-market trade.
    28 Feb 2024 Andrew Grant Buy 130,000 $10,920
    On-market trade.
    28 Feb 2024 Christine Emmanuel-Donnelly Buy 121,952 $10,169
    On-market trade.
    14 Dec 2023 Janelle Delaney Buy 942,232 $135,148
    On-market trade.
    13 Dec 2023 Christine Emmanuel-Donnelly Buy 67,857 $9,499
    On-market trade.
    05 Dec 2023 Janelle Delaney Buy 66,503 $8,977
    On-market trade.
    04 Dec 2023 Andrew Grant Buy 70,000 $9,625
    On-market trade.
    20 Nov 2023 Richard Valencia Expiry 10,000,000 $1,300,000
    Options expired.
    20 Nov 2023 Richard Valencia Expiry 20,000,000 $2,600,000
    As advised by the company. Lapse of Options and Performance Rights
    01 Nov 2023 Christine Emmanuel-Donnelly Buy 100,000 $10,500
    On-market trade.
    03 Jul 2023 David Anderson Issued 81,325 $13,499
    Director remuneration.
    03 Jul 2023 Janet West Issued 130,152 $21,605
    Director remuneration.
    03 Jul 2023 Amit Patel Issued 111,145 $18,450
    Director remuneration.
    03 Jul 2023 Donald (Don) Williams Issued 178,916 $29,700
    Director remuneration.
    20 Jun 2023 David Anderson Buy 920,000 $143,980
    On-market trade.
    13 Jun 2023 Janet West Buy 300,000 $46,500
    On-market trade.
    13 Jun 2023 Donald (Don) Williams Buy 1,000,000 $157,500
    On-market trade.
    06 Jun 2023 Donald (Don) Williams Transfer 130,000 $20,150
    Off-market transfer.
    06 Jun 2023 Donald (Don) Williams Transfer 130,000 $20,150
    Off-market transfer.
    06 Jun 2023 Donald (Don) Williams Buy 500,000 $82,300
    On-market trade.
    27 Apr 2023 Donald (Don) Williams Buy 100,000 $17,500
    On-market trade.
    20 Apr 2023 Richard Valencia Buy 410,000 $51,824
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Parmjot Bains Managing DirectorInterim CEO Jan 2024
    Dr Bains is a healthcare executive with experience including strategy, sales & marketing, commercial execution, and change management across the US, Asia, Middle East and Australia. Dr Bains joined Pfizer US in 2015 and since then has held several roles located in the United States, Asia Pacific and Middle East. Most recently, Dr Bains was Pfizers Gulf Cluster Country Manager, responsible for setting commercial strategy, aligning team capabilities, driving private and public reimbursement, accelerating sales & marketing activities and key account management. Dr Bains managed a large team across six countries and six therapeutic areas (including breast cancer). Dr Bains former roles include: joint CEO and Chief Operating Officer at Neuren Pharmaceuticals (ASX: NEU) (developing therapies for brain injury, neurodevelopmental and neurodegenerative disorder); CEO of Perseis Therapeutics, (creating monoclonal antibody candidates against breast cancer targets); manager at McKinsey and Company and medical doctor.
    Mr Andrew John Grant Non-Executive Director Sep 2023
    --
    Mr McGregor Grant Executive ChairmanExecutive DirectorInterim CFO Nov 2023
    --
    Ms Christine Emmanuel-Donnelly Non-Executive Director Sep 2023
    --
    Ms Janelle Delaney Non-Executive Director Sep 2023
    --
    Ms Leanne Ralph Company Secretary Jan 2015
    -
    Timothy Cruickshank Chief Financial Officer
    -
    Shashi Tripathi Chief Operating Officer
    -
    Joann Yao Chief Strategy Officer
    -
    Leanne Ralph Company Secretary
    -
    Dennis Schlaht Senior Vice President R&D and Technology
    -
    Lisa Prom Vice President Sales
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    National Nominees Limited 190,580,959 9.44%
    Citicorp Nominees Pty Limited 176,271,813 8.73%
    J P Morgan Nominees Australia Pty Limited 122,801,902 6.08%
    HSBC Custody Nominees (Australia) Limited 86,660,527 4.29%
    Bnp Paribas Noms Pty Ltd 71,262,491 3.53%
    BNP Paribas Nominees Pty Ltd 56,357,329 2.79%
    HSBC Custody Nominees (Australia) Limited i 47,593,537 2.36%
    HSBC Custody Nominees (Australia) Limited A/C 2 28,525,714 1.42%
    Moore Family Nominee Pty Ltd 22,500,000 1.11%
    Mba Investments Pty Ltd 22,490,990 1.11%
    Mr Hamish Alexander Jones 21,263,705 1.05%
    Mr Gregory Wayne Brown 21,100,000 1.05%
    Sunlora Pty Ltd 19,000,000 0.94%
    Apex Investment Management Pty Limited 17,471,778 0.87%
    BNP Paribas Nominees Pty Ltd i 16,201,010 0.82%
    Pakasoluto Pty Limited 16,011,422 0.79%
    Mr Stephen Edward Mahnken & Mrs Dior Leone Mahnken 16,000,000 0.79%
    Dr Hsien Michael Soo 15,394,710 0.76%
    Bsd Pty Ltd 13,300,000 0.66%
    Mid Dig Investments Pty Ltd 12,970,633 0.64%

    Profile

    since

    Note